
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories has demonstrated robust growth across multiple divisions, with the Medical Device segment achieving a 14% year-over-year increase in sales, reflecting strong demand for its innovative products, including catheters and cardiac mapping devices. The company anticipates organic sales growth of 7.5-8.5% for 2025, indicating stability and resilience in its revenue stream, even when excluding COVID-19 testing-related sales. Additionally, Abbott's commitment to returning value to shareholders is evident through its nearly 50 consecutive years of dividend increases, with a sustainable payout ratio of 46% and a yield of 1.8%.
Bears say
Abbott Laboratories is facing significant headwinds due to declining COVID-19 testing sales, which fell sharply from $8.4 billion in 2022 to $1.6 billion in 2023, impacting overall revenue performance. The company is also contending with greater macroeconomic pressures, including inflation and foreign exchange fluctuations, which are expected to challenge financial outcomes in both the first quarter and full-year 2025. Additionally, anticipated limitations to international expansion due to geopolitical factors and increased investments will likely constrain earnings power, further contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares